CBDepot launches synthesized pharma-grade CBD to global market

news-releasesCBDepot s.r.o.
November 3rd 2021

Teplice, Czech Republic: – Pioneering producer and B2B supplier of upmarket cannabinoid solutions, CBDepot group, has commenced marketing of synthesized pharma-grade cannabidiol (CBD) as a cGMP product for European markets.

The newly-launched synthesized pharma-grade CBD is compliant with the German DAC monograph.

In-house manufacturing

The synthesized GMP grade CBD is being marketed under the brand of CBDepot sister company , CB21 Pharma, s.r.o, which recently  obtained GMP certification for its CBD manufacturing operations at its facility in Brno, Czech Republic.

Since summer 2019, the group has brought API Cannabidiol manufacture entirely in-house, with the opening of the new CB21 Pharma Brno production facility.

At CPhI Worldwide 2017 in Frankfurt, CBDepot became the first company in the EU to introduce GMP standard isolated CBD, using a 3rd party contract manufacturer in Prague. This latest move extends CBDepot’s range of marketed GMP CBD to include a synthesized product.

GMP grade synthesized CBD

Dr. Jan Storch, the CEO of CB21 Pharma, commented: “This allows CB21 Pharma to bring to the pharmaceutical markets both synthesized and isolated Cannabidiol APIs through exclusive distribution and brokerage arrangements with CBDepot.”

CBDepot Group Chief Sales Officer, Boris Baňas, added: “This addition will serve growing needs for GMP-grade product in applications or jurisdictions where the use of plant-based Cannabidiol API is not possible.”

About CBDepot

CBDepot is an innovative and recognized producer and B2B supplier of upmarket natural and synthesized cannabinoid ingredients to fast-growing markets in the food, cosmetics, pharmaceuticals and health products industries sectors.

CBDepot specializes in bulk supply of cannabinoid-based ingredients for food, cosmetics and pharmaceutical sectors. Its products ensure that content of tetrahydrocannabinol (THC), the main intoxicating element of cannabis, is below detectable levels. Instead, its products emphasize the two other main natural ingredients, cannabidiol (CBD) and cannabigerol (CBG).

Established in 2014, CBDepot has become a leader in helping to establish legal and quality standards for cannabinoid ingredients and the formulation of cannabidiol derivatives. Since foundation it has operated under legal license granted by the government of the Czech Republic.

The company’s initial mission was the supply of “Legal and Quality CBD” at a time when sourcing ethical and quality isolated CBD was a challenge. CBDepot’s scientific knowledge is based on close links with the Czech Academy of Sciences.

The company’s Chief Sales Officer, Boris Baňas, is an ex-board member of the European Industrial Hemp Association (EIHA), where he successfully campaigned for the establishment of new Europe-wide standards.


Click on CBDepot group announces new EU GMP compliant manufacturing site for Cannabidiol APIs for further information.
Click on Isolated pharma-grade trans-Cannabidiol for product information.

CBDepot launches synthesized pharma-grade CBD to global market

CBDepot isolated Cannabidiol (CBD) powder

CBDepot launches synthesized pharma-grade CBD to global market

Boris Baňas, Chief Scientific Officer, CBDepot